Search research articles
Contact Us
Filters
Showing results (11-20 of 25) with videos related to
Page
of 3
Sort By:
Plos One
|
February 3, 2017
Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes
Pepijn Vemer, Maiwenn J Al, Mark Oppe, et al.
Pharmacoeconomics
|
June 6, 2013
A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes
Pepijn Vemer, Maiwenn J Al, Mark Oppe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 2, 2017
A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data
Isaac Corro Ramos, George A K van Voorn, Pepijn Vemer, et al.
Neuropsychiatric Disease and Treatment
|
November 5, 2013
Let's get back to work: survival analysis on the return-to-work after depression
Pepijn Vemer, Clazien A Bouwmans, Moniek C Zijlstra-Vlasveld, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 12, 2020
Author's Reply
Simon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 30, 2019
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier
Simon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Applied Health Economics and Health Policy
|
September 20, 2015
The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling
George A K van Voorn, Pepijn Vemer, Dominique Hamerlijnck, et al.
BMC Public Health
|
June 3, 2014
Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe
Diana Divajeva, Tim Marsh, Susanne Logstrup, et al.
Pharmacoeconomics
|
September 22, 2017
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
Thea van Asselt, Bram Ramaekers, Isaac Corro Ramos, et al.
Addiction (Abingdon, England)
|
July 28, 2010
If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands
Pepijn Vemer, Maureen P M H Rutten-van Mölken, Janneke Kaper, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 25) with videos related to
Sort By:
Page
of 3
Plos One
|
February 3, 2017
Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes
Pepijn Vemer, Maiwenn J Al, Mark Oppe, et al.
Pharmacoeconomics
|
June 6, 2013
A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes
Pepijn Vemer, Maiwenn J Al, Mark Oppe, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
October 2, 2017
A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data
Isaac Corro Ramos, George A K van Voorn, Pepijn Vemer, et al.
Neuropsychiatric Disease and Treatment
|
November 5, 2013
Let's get back to work: survival analysis on the return-to-work after depression
Pepijn Vemer, Clazien A Bouwmans, Moniek C Zijlstra-Vlasveld, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 12, 2020
Author's Reply
Simon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
September 30, 2019
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier
Simon van der Pol, Lisa A de Jong, Pepijn Vemer, et al.
Applied Health Economics and Health Policy
|
September 20, 2015
The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling
George A K van Voorn, Pepijn Vemer, Dominique Hamerlijnck, et al.
BMC Public Health
|
June 3, 2014
Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe
Diana Divajeva, Tim Marsh, Susanne Logstrup, et al.
Pharmacoeconomics
|
September 22, 2017
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research
Thea van Asselt, Bram Ramaekers, Isaac Corro Ramos, et al.
Addiction (Abingdon, England)
|
July 28, 2010
If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands
Pepijn Vemer, Maureen P M H Rutten-van Mölken, Janneke Kaper, et al.
Page
of 3